Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ ...

At first glance, CHAMPION-AF gives some redemption to LAA occluders after CLOSURE-AF, a smaller randomized trial that failed to show that LAA closure (using various devices) was non-inferior to NOAC ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

In patients with atrial fibrillation, those assigned left atrial appendage closure had similar ischemic outcomes and better bleeding outcomes compared with those assigned oral anticoagulation, ...